Serum Metabolomics Profiles for Cerebral Infarction Patients and Controls

3,160 metabolites were identified in serum samples from 10 cerebral infarction patients and 10 control subjects. The dataset, created by Dayong Guo and last updated in April 2026, reveals distinct metabolic signatures, including elevated benzene derivatives and reduced amino acids in patients. It provides a basis for biomarker screening and pathological mechanism studies.

Use Cases

• Identify potential biomarkers for cerebral infarction based on differential metabolite levels.
• Analyze metabolic reprogramming patterns between patient and control groups.
• Investigate correlations between lipid metabolites and benzene derivatives as described.
• Perform enrichment analysis on pathways involved in lipid and amino acid metabolism.

Strengths

• Includes 329 differential metabolites identified between the two groups.
• Provides proportions for major metabolite classes, such as benzene derivatives (15.71%) in patients.
• Clear separation between groups demonstrated by PCA and OPLS-DA models.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Sample size is limited to 10 patients and 10 controls.

Provenance

Source

figshare

Collection Method

LC-MS-based serum metabolomics analysis.

Freshness

Last updated 2026-04-09 05:15:40; freshness should be verified.